Multi-block/JJ
Analysis/NN
of/IN
Genomic/JJ
Data/NNS
Using/VBG
Generalized/JJ
Canonical/JJ
Correlation/NN
Analysis/NN
./.
====================
Recently/RB
,/,
there/EX
have/VBP
been/VBN
many/JJ
studies/NNS
in/IN
medicine/NN
related/JJ
to/TO
genetic/JJ
analysis/NN
./.
====================
Many/JJ
genetic/JJ
studies/NNS
have/VBP
been/VBN
performed/VBN
to/TO
find/VB
genes/NNS
associated/VBN
with/IN
complex/NN
diseases/NNS
./.
====================
To/TO
find/VB
out/IN
how/WRB
genes/NNS
are/VBP
related/JJ
to/TO
disease/NN
,/,
we/PRP
need/VBD
to/TO
understand/VB
not/RB
only/RB
the/DT
simple/JJ
relationship/NN
of/IN
genotypes/NNS
but/CC
also/RB
the/DT
way/NN
they/PRP
are/VBP
related/JJ
to/TO
phenotype/NN
./.
====================
Multi-block/JJ
data/NNS
,/,
which/WDT
is/VBZ
a/DT
summation/NN
form/VBP
of/IN
variable/JJ
sets/NNS
,/,
is/VBZ
used/VBN
for/IN
enhancing/VBG
the/DT
analysis/NN
of/IN
the/DT
relationships/NNS
of/IN
different/JJ
blocks/NNS
./.
====================
By/IN
identifying/VBG
relationships/NNS
through/IN
a/DT
multi-block/JJ
data/NNS
form/VBP
,/,
we/PRP
can/MD
understand/VB
the/DT
association/NN
between/IN
the/DT
blocks/NNS
in/IN
comprehending/VBG
the/DT
correlation/NN
between/IN
them/PRP
./.
====================
Several/JJ
statistical/JJ
analysis/NN
methods/NNS
have/VBP
been/VBN
developed/VBN
to/TO
understand/VB
the/DT
relationship/NN
between/IN
multi-block/JJ
data/NNS
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
will/MD
use/VB
generalized/VBN
canonical/JJ
correlation/NN
methodology/NN
to/TO
analyze/VB
multi-block/JJ
data/NNS
from/IN
the/DT
Korean/JJ
Association/NN
Resource/NN
project/VB
,/,
which/WDT
has/VBZ
a/DT
combination/NN
of/IN
single/JJ
nucleotide/NN
polymorphism/NN
blocks/VBZ
,/,
phenotype/NN
blocks/VBZ
,/,
and/CC
disease/NN
blocks/VBZ
./.
====================
Human/JJ
diseases/NNS
involve/VBP
complex/NN
processes/NNS
,/,
including/VBG
the/DT
interaction/NN
between/IN
multiple/JJ
biological/JJ
layers/NNS
,/,
including/VBG
genetic/JJ
,/,
epigenetic/JJ
,/,
and/CC
transcriptional/JJ
regulation/NN
[/(
1/CD
]/)
./.
====================
For/IN
identifying/VBG
genes/NNS
involved/VBN
in/IN
complex/NN
human/JJ
diseases/NNS
,/,
genome-wide/NN
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
are/VBP
used/VBN
by/IN
searching/VBG
for/IN
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
that/WDT
occur/VBP
more/RBR
frequently/RB
in/IN
people/JJ
without/IN
the/DT
disease/NN
./.
====================
Prior/JJ
GWASs/NNS
identified/VBN
SNPs/NNS
related/JJ
to/TO
several/JJ
complex/NN
diseases/NNS
,/,
such/JJ
as/IN
diabetes/NNS
,/,
heart/NN
abnormalities/NNS
,/,
and/CC
Parkinson/NN
disease/NN
./.
====================
Researchers/NNS
hope/NN
to/TO
find/VB
more/RBR
SNPs/NNS
associated/VBN
with/IN
chronic/JJ
diseases/NNS
through/IN
GWASs/NNS
in/IN
the/DT
future/JJ
[/(
2/CD
]/)
./.
====================
Most/JJS
research/NN
has/VBZ
focused/VBN
solely/RB
on/IN
the/DT
investigation/NN
of/IN
a/DT
single/JJ
type/NN
of/IN
genomic/JJ
data/NNS
[/(
3/CD
]/)
./.
====================
However/RB
,/,
recent/JJ
advances/NNS
in/IN
genotyping/VBG
technology/NN
have/VBP
resulted/VBD
in/IN
the/DT
large-scale/JJ
generation/NN
of/IN
genomic/JJ
data/NNS
,/,
and/CC
the/DT
variety/NN
of/IN
information/NN
collected/JJ
has/VBZ
also/RB
become/VBP
very/RB
diverse/JJ
./.
====================
Therefore/RB
,/,
it/PRP
has/VBZ
become/VBN
very/RB
important/JJ
to/TO
apply/RB
analytical/JJ
methods/NNS
that/DT
can/MD
fully/RB
utilize/VBP
the/DT
given/VBN
information/NN
./.
====================
These/DT
data/NNS
need/VBD
to/TO
be/VB
analyzed/VBN
in/IN
conjunction/NN
with/IN
disease/NN
variables/NNS
,/,
such/JJ
as/IN
multiple/JJ
SNPs/NNS
and/CC
phenotypes/NNS
./.
====================
However/RB
,/,
since/IN
these/DT
variables/NNS
have/VBP
different/JJ
properties/NNS
from/IN
each/DT
other/JJ
,/,
multi-block/JJ
analysis/NN
that/IN
considers/VBZ
each/DT
property/NN
is/VBZ
necessary/JJ
./.
====================
Furthermore/RB
,/,
even/RB
though/IN
these/DT
data/NNS
have/VBP
the/DT
potential/JJ
to/TO
reveal/VB
great/JJ
insights/NNS
into/IN
the/DT
mechanism/NN
of/IN
disease/NN
and/CC
to/TO
discover/RB
novel/JJ
biomarkers/NNS
,/,
statistical/JJ
methods/NNS
for/IN
integrative/JJ
analysis/NN
of/IN
multi-block/JJ
data/NNS
are/VBP
only/RB
emerging/VBG
[/(
4/CD
]/)
./.
====================
If/IN
there/EX
are/VBP
only/RB
two/CD
variable/JJ
blocks/VBZ
,/,
canonical/JJ
correlation/NN
analysis/NN
(/(
CCA/NN
)/)
can/MD
be/VB
applied/VBN
./.
====================
Research/NN
continues/NNS
to/TO
try/NN
to/TO
analyze/VB
DNA-related/JJ
data/NNS
based/VBN
on/IN
canonical/JJ
analysis/NN
./.
====================
Briki/DT
and/CC
Genest/NN
[/(
5/CD
]/)
adopted/JJ
a/DT
canonical/JJ
analysis/NN
approach/NN
to/TO
investigate/VB
correlated/VBD
motions/NNS
of/IN
atoms/NNS
by/IN
molecular/JJ
dynamics/NNS
simulation/JJ
./.
====================
However/RB
,/,
since/IN
there/EX
are/VBP
more/RBR
than/IN
two/CD
blocks/NNS
in/IN
reality/NN
,/,
the/DT
extended/JJ
CCA/NN
methods/NNS
that/DT
are/VBP
applicable/JJ
to/TO
more/RBR
than/IN
two/CD
blocks/NNS
have/VBP
been/VBN
less/RBR
studied/VBN
./.
====================
Hence/RB
,/,
research/NN
has/VBZ
recently/RB
started/VBD
to/TO
shift/VB
toward/IN
approaches/NNS
using/VBG
systematical/JJ
models/NNS
in/IN
order/NN
to/TO
integrate/VB
and/CC
analyze/VB
heterogeneous/JJ
data/NNS
comprehensively/RB
rather/RB
than/IN
through/IN
simple/JJ
step-wise/RB
processes/NNS
./.
====================
Among/IN
multi-block/JJ
analysis/NN
methods/NNS
,/,
generalized/VBN
canonical/JJ
correlation/NN
analysis/NN
(/(
GCCA/NN
)/)
is/VBZ
one/CD
of/IN
the/DT
most/JJS
representative/JJ
methods/NNS
./.
====================
Nevertheless/RB
,/,
many/JJ
studies/NNS
have/VBP
not/RB
yet/RB
been/VBN
conducted/VBN
on/IN
the/DT
application/NN
of/IN
multi-block/JJ
methods/NNS
to/TO
genomic/JJ
data/NNS
./.
====================
Therefore/RB
,/,
in/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
adopt/VBP
GCCA/NN
to/TO
figure/NN
out/IN
the/DT
associations/NNS
between/IN
SNP/NN
block/VBP
,/,
phenotype/NN
block/VBP
,/,
and/CC
disease/NN
block/VBP
./.
====================
We/PRP
applied/VBD
Korean/JJ
Association/NN
Resource/NN
(/(
KARE/NN
)/)
data/NNS
and/CC
analyzed/VBD
the/DT
possibility/NN
and/CC
limitations/NNS
of/IN
multi-block/JJ
analysis/NN
methods/NNS
for/IN
genomic/JJ
data/NNS
./.
====================
Multi-block/JJ
dataset/NN
====================
We/PRP
focused/VBD
on/IN
analyzing/VBG
a/DT
multi-block/JJ
dataset/NN
,/,
considering/VBG
the/DT
characteristics/NNS
of/IN
each/DT
block/VBP
./.
====================
The/DT
multi-block/JJ
dataset/NN
is/VBZ
a/DT
data/NNS
type/NN
of/IN
horizontally/RB
concatenating/VBG
more/RBR
than/IN
two/CD
variable/JJ
blocks/VBZ
./.
====================
Usually/RB
,/,
each/DT
block/VBP
has/VBZ
different/JJ
properties/NNS
and/CC
forms/NNS
and/CC
can/MD
also/RB
be/VB
partitioned/VBN
by/IN
prior/JJ
knowledge/NN
,/,
but/CC
all/DT
blocks/VBZ
have/VBP
the/DT
same/JJ
number/NN
of/IN
observations/NNS
./.
====================
Suppose/NN
there/EX
are/VBP
K/NN
blocks/VBZ
,/,
and/CC
each/DT
block/VBP
has/VBZ
pk/NN
number/NN
of/IN
variables/NNS
(/(
k/NN
=/JJ
1/CD
,/,
···/CD
,/,
K/NN
)/)
./.
====================
We/PRP
can/MD
express/VB
the/DT
k-th/NN
block/VBP
Xk/JJ
as/IN
Xk/JJ
=/JJ
[/(
x1/NN
,/,
···/CD
,/,
xpk/VBP
]/)
./.
====================
The/DT
total/JJ
dataset/NN
X/NN
can/MD
be/VB
presented/VBN
as/IN
[/(
X1/NN
,/,
···/CD
,/,
Xk/NN
,/,
···/CD
,/,
XK/NN
]/)
./.
====================
As/IN
technology/NN
advances/NNS
,/,
this/DT
type/NN
of/IN
data/NNS
is/VBZ
common/JJ
in/IN
a/DT
variety/NN
of/IN
studies/NNS
./.
====================
For/IN
instance/NN
,/,
in/IN
food/NN
science/NN
,/,
blocks/VBZ
of/IN
variables/NNS
could/MD
be/VB
physico-chemical/JJ
measurements/NNS
,/,
sensory/JJ
analysis/NN
data/NNS
,/,
and/CC
instrumental/JJ
measurements/NNS
[/(
6/CD
]/)
./.
====================
Multiomics/NNS
,/,
the/DT
typical/JJ
multi-block/JJ
dataset/NN
in/IN
the/DT
medical/JJ
field/NN
,/,
means/NNS
a/DT
new/JJ
biological/JJ
analysis/NN
approach/VBP
where/WRB
the/DT
datasets/NNS
are/VBP
multiple/JJ
omics/NNS
,/,
such/JJ
as/IN
the/DT
genome/NN
,/,
proteome/DT
,/,
transcriptome/DT
,/,
epigenome/DT
,/,
and/CC
microbiome/NN
[/(
7–9/CD
]/)
./.
====================
It/PRP
usually/RB
focuses/VBZ
on/IN
associations/NNS
between/IN
SNPs/NNS
and/CC
traits/VBZ
,/,
considering/VBG
varying/VBG
phenotypes/NNS
./.
====================
Generalized/VBN
canonical/JJ
correlation/NN
analysis/NN
====================
Among/IN
various/JJ
methods/NNS
of/IN
dealing/VBG
with/IN
a/DT
multi-block/JJ
dataset/NN
,/,
GCCA/NN
is/VBZ
used/VBN
in/IN
this/DT
paper/NN
./.
====================
Since/IN
it/PRP
is/VBZ
extended/VBN
from/IN
CCA/NN
,/,
we/PRP
start/VBP
with/IN
an/DT
explanation/NN
of/IN
CCA/NN
./.
====================
CCA/NN
is/VBZ
a/DT
method/NN
of/IN
inferring/VBG
information/NN
from/IN
cross-covariance/NN
matrices/NNS
./.
====================
If/IN
there/EX
are/VBP
two/CD
vectors/NNS
X/NN
=/JJ
(/(
x1/NN
,/,
···/NNP
,/,
xn/CC
)/)
and/CC
Y/NN
=/JJ
(/(
y1/LS
,/,
···/NNP
,/,
ym/RB
)/)
of/IN
random/JJ
variables/NNS
and/CC
if/IN
there/EX
are/VBP
correlations/NNS
among/IN
the/DT
variables/NNS
,/,
the/DT
linear/JJ
combinations/NNS
of/IN
xi/DT
and/CC
yj/RB
to/TO
maximize/VB
the/DT
correlation/NN
with/IN
each/DT
other—termed/VBN
canonical/JJ
variables—/IN
are/VBP
found/VBN
through/IN
CCA/NN
[/(
10/CD
]/)
./.
====================
GCCA/NNS
is/VBZ
a/DT
way/NN
of/IN
extending/VBG
CCA/NN
to/TO
adapt/VB
to/TO
more/RBR
than/IN
two/CD
sets/NNS
of/IN
random/JJ
variables/NNS
after/IN
removing/VBG
dependencies/VBZ
within/IN
each/DT
set/NN
./.
====================
The/DT
basic/JJ
structure/NN
of/IN
CCA/NN
is/VBZ
to/TO
derive/VB
a/DT
new/JJ
linear/JJ
combination/NN
of/IN
the/DT
variables/NNS
,/,
called/VBN
canonical/JJ
variables/NNS
,/,
constituting/VBG
each/DT
set/NN
and/CC
to/TO
estimate/VB
the/DT
correlation/NN
between/IN
canonical/JJ
variables/NNS
./.
====================
In/IN
other/JJ
words/NNS
,/,
canonical/JJ
variables/NNS
summarize/VBP
the/DT
information/NN
inherent/JJ
to/TO
the/DT
abbreviated/JJ
set/NN
of/IN
multivariate/JJ
data/NNS
[/(
11/CD
]/)
./.
====================
GCCA/NNS
can/MD
be/VB
divided/VBN
into/IN
two/CD
methods/NNS
:/:
using/VBG
correlations/NNS
and/CC
using/VBG
covariance/NN
./.
====================
In/IN
our/PRP$
paper/NN
,/,
we/PRP
use/VBP
a/DT
method/NN
of/IN
analysis/NN
based/VBN
on/IN
covariance/NN
./.
====================
GCCA/NNS
based/VBN
on/IN
covariance/NN
uses/VBZ
the/DT
variance/NN
of/IN
‘/NN
block/VBP
scores/NNS
’/CD
to/TO
compute/VB
the/DT
residual/JJ
matrices/NNS
./.
====================
For/IN
instance/NN
,/,
in/IN
an/DT
Xk/NN
variable/JJ
block/VBP
,/,
we/PRP
can/MD
denote/VB
ak/NN
=/JJ
(/(
ak1/NN
ak2/NN
···/CD
akpk/VBP
)/)
′/CD
as/IN
the/DT
coefficients/NNS
for/IN
each/DT
variable/JJ
in/IN
Xk/JJ
block/VBP
./.
====================
Therefore/RB
,/,
the/DT
canonical/JJ
variables/NNS
,/,
yk/NN
(/(
k/NN
=/JJ
1/CD
,/,
···/CD
,/,
K/NN
)/)
,/,
are/VBP
expressed/VBN
as/IN
:/:
====================
y/RB
1/CD
=/JJ
X/NN
1/CD
a/DT
1/CD
=/JJ
a/DT
11/CD
X/NN
11/CD
+/JJ
⋯/NN
+/CC
a/DT
1/CD
p/NN
1/CD
X/NN
1/CD
p/NN
1/CD
⋮/NN
y/RB
K/NN
=/JJ
X/NN
K/NN
a/DT
K/NN
=/JJ
a/DT
K/NN
1/CD
X/NN
K/NN
1/CD
+/CC
⋯/NN
+/CC
a/DT
K/NN
p/NN
K/NN
X/NN
K/NN
p/NN
K/NN
====================
The/DT
optimization/NN
problem/NN
is/VBZ
as/IN
follows/VBZ
./.
====================
argmax/NN
{/CD
a/DT
1/CD
,/,
a/DT
2/CD
⋯/CD
a/DT
k/JJ
}/CD
∑/CD
i/LS
,/,
j/RB
=/JJ
1/CD
,/,
i/LS
≠/CD
j/RB
K/NN
c/NN
i/LS
j/RB
g/NN
(/(
c/NN
o/RB
v/LS
(/(
X/NN
i/LS
a/DT
i/LS
,/,
X/NN
j/RB
a/DT
j/JJ
)/)
)/)
====================
The/DT
optimization/NN
problem/NN
tries/NNS
to/TO
find/VB
coefficients/NNS
of/IN
each/DT
block/VBP
a1/NN
,/,
a2/NN
,/,
···/NNP
,/,
aK/NN
that/DT
would/MD
maximize/VB
the/DT
weighted/JJ
summation/NN
of/IN
the/DT
covariance/NN
of/IN
the/DT
two/CD
components/NNS
./.
====================
The/DT
cij/JJ
in/IN
the/DT
equation/NN
implies/VBZ
the/DT
relationship/NN
between/IN
variable/JJ
block/VBP
Xi/JJ
and/CC
Xj/JJ
./.
====================
If/IN
they/PRP
have/VBP
a/DT
relationship/NN
,/,
we/PRP
could/MD
assign/VB
cij/NN
=/JJ
1/CD
;/:
otherwise/RB
,/,
we/PRP
could/MD
assign/VB
cij/NN
=/JJ
0/CD
./.
====================
The/DT
function/NN
g/NN
(/(
)/)
can/MD
be/VB
various/JJ
functions/NNS
,/,
such/JJ
as/IN
horst/JJ
(/(
g/NN
(/(
x/CC
)/)
=/JJ
x/CC
)/)
,/,
centroid/JJ
(/(
g/NN
(/(
x/CC
)/)
=/JJ
|x|/CD
)/)
,/,
and/CC
factorial/JJ
(/(
g/NN
(/(
x/CC
)/)
=/JJ
x2/NN
)/)
./.
====================
Among/IN
these/DT
methods/NNS
,/,
we/PRP
applied/VBD
horst/JJ
methods/NNS
./.
====================
A/DT
design/NN
matrix/NN
C/NN
=/JJ
(/(
cjk/NN
)/)
is/VBZ
pre-specified/VBN
by/IN
the/DT
user/NN
to/TO
express/VB
the/DT
relationships/NNS
between/IN
blocks/VBZ
./.
====================
The/DT
element/NN
cjk/NN
is/VBZ
equal/JJ
to/TO
1/CD
if/IN
block/VBP
j/RB
and/CC
block/VBP
k/NN
are/VBP
connected/VBN
and/CC
0/CD
otherwise/RB
[/(
12/CD
,/,
13/CD
]/)
./.
====================
Data/NNS
description/NN
:/:
KARE/NN
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
use/VBP
data/NNS
from/IN
the/DT
KARE/NN
project/VB
,/,
which/WDT
was/VBD
initiated/VBN
in/IN
2007/CD
to/TO
undertake/VB
a/DT
large-scale/JJ
genome-wide/NN
association/NN
analysis/NN
among/IN
the/DT
10,038/NN
participants/NNS
of/IN
two/CD
areas/NNS
:/:
Anseong/JJ
and/CC
Ansan/NN
./.
====================
It/PRP
was/VBD
established/VBN
as/IN
part/NN
of/IN
the/DT
Korean/JJ
Genome/NN
Epidemiology/NN
study/NN
(/(
KoGES/NN
)/)
in/IN
2001/CD
,/,
providing/VBG
genomic/JJ
and/CC
clinical/JJ
variables/NNS
for/IN
over/IN
260/CD
traits/VBZ
[/(
14/CD
]/)
./.
====================
Among/IN
the/DT
KARE/NN
data/NNS
,/,
we/PRP
decided/VBD
to/TO
make/VB
three/CD
different/JJ
variable/JJ
blocks/VBZ
that/DT
included/VBD
information/NN
on/IN
SNP/NN
variables/NNS
,/,
phenotype/NN
variables/NNS
,/,
and/CC
disease/NN
variables/NNS
./.
====================
Fig/NN
./.
====================
1/CD
represents/VBZ
the/DT
multi-block/JJ
form/VBP
of/IN
the/DT
KARE/NN
data/NNS
,/,
which/WDT
had/VBD
three/CD
variable/JJ
blocks/VBZ
,/,
each/DT
with/IN
different/JJ
characteristics/NNS
./.
====================
The/DT
first/JJ
variable/JJ
block/VBP
,/,
X1/NN
,/,
is/VBZ
a/DT
block/NN
of/IN
SNP/NN
variables/NNS
;/:
the/DT
second/JJ
variable/JJ
block/VBP
,/,
X2/NN
,/,
is/VBZ
a/DT
phenotype/NN
block/VBP
that/IN
has/VBZ
five/CD
phenotype/NN
variables/NNS
related/JJ
to/TO
obesity/NN
./.
====================
The/DT
last/JJ
variable/JJ
block/VBP
,/,
X3/NN
,/,
is/VBZ
a/DT
disease/NN
block/VBP
that/IN
has/VBZ
information/NN
on/IN
observational/JJ
status/NN
in/IN
diabetes/NNS
and/CC
hypertension/NN
./.
====================
The/DT
first/JJ
variable/JJ
block/VBP
,/,
X1/NN
,/,
has/VBZ
information/NN
on/IN
35/CD
SNP/NN
variables/NNS
,/,
and/CC
each/DT
piece/NN
of/IN
data/NNS
was/VBD
recorded/VBN
as/IN
0/CD
,/,
1/CD
,/,
or/CC
2/CD
according/VBG
to/TO
their/PRP$
genotype/NN
./.
====================
We/PRP
extracted/VBD
35/CD
SNP/NN
variables/NNS
to/TO
be/VB
included/VBN
in/IN
our/PRP$
analysis/NN
according/VBG
to/TO
the/DT
specific/JJ
following/VBG
steps/NNS
described/VBN
in/IN
Fig/NN
./.
====================
2/CD
./.
====================
The/DT
original/JJ
KARE/NN
dataset/NN
has/VBZ
311,779/CD
variables/NNS
,/,
and/CC
we/PRP
regarded/VBD
324/CD
SNP/NN
variables/NNS
as/IN
our/PRP$
main/JJ
interest/NN
from/IN
the/DT
literature/NN
of/IN
Multi-QMDR/JJ
analysis/NN
./.
====================
The/DT
324/CD
SNP/NN
variables/NNS
showed/VBD
strong/JJ
marginal/JJ
effects/NNS
in/IN
the/DT
univariate/JJ
linear/JJ
regression/NN
models/NNS
in/IN
the/DT
paper/NN
[/(
15/CD
]/)
./.
====================
From/IN
the/DT
324/CD
selected/VBN
variables/NNS
,/,
we/PRP
selected/VBD
47/CD
variables/NNS
that/DT
showed/VBD
a/DT
significant/JJ
relationship/NN
with/IN
our/PRP$
phenotype/NN
variables/NNS
in/IN
the/DT
phenotype/NN
block/VBP
./.
====================
Lastly/RB
,/,
we/PRP
removed/VBD
extremely/RB
similar/JJ
SNP/NN
variables/NNS
that/DT
had/VBD
a/DT
correlation/NN
of/IN
more/RBR
than/IN
0.98/CD
with/IN
each/DT
other/JJ
in/IN
order/NN
to/TO
clearly/RB
see/VB
the/DT
correlation/NN
between/IN
variables/NNS
./.
====================
The/DT
second/JJ
variable/JJ
block/VBP
,/,
X2/NN
,/,
is/VBZ
a/DT
block/NN
of/IN
phenotype/NN
variables/NNS
that/DT
have/VBP
been/VBN
proven/VBN
to/TO
have/VB
a/DT
relationship/NN
with/IN
obesity/NN
./.
====================
The/DT
five/CD
phenotype/NN
variables–suprailiac/NN
skinfold/JJ
,/,
subscapular/JJ
skinfold/JJ
,/,
body/NN
mass/NN
index/NN
(/(
BMI/NN
)/)
,/,
waist-hip/NN
ratio/NN
,/,
and/CC
waist–were/VBD
selected/VBN
,/,
and/CC
all/DT
of/IN
them/PRP
are/VBP
related/JJ
to/TO
obesity/NN
./.
====================
The/DT
third/JJ
variable/JJ
block/VBP
,/,
X3/NN
,/,
is/VBZ
a/DT
block/NN
of/IN
diseases/NNS
./.
====================
Two/CD
disease/NN
variables/NNS
were/VBD
made/VBN
from/IN
patients/NNS
’/CD
clinical/JJ
traits/NNS
./.
====================
Participants/NNS
whose/WP$
“/CD
fasting/VBG
blood/NN
glucose/NN
”/NN
was/VBD
higher/JJR
than/IN
126/CD
,/,
“/NNP
blood/NN
glucose/oral/JJ
glucose/NN
tolerance/NN
after/IN
120/CD
minutes/NNS
”/NN
was/VBD
higher/JJR
than/IN
200/CD
,/,
or/CC
“/JJ
who/WP
had/VBD
medication/NN
of/IN
diabetes/NNS
”/CD
were/VBD
considered/VBN
as/IN
having/VBG
diabetes/NNS
./.
====================
Participants/NNS
whose/WP$
“/CD
subscapular/JJ
skinfold/JJ
”/CD
was/VBD
over/IN
140/CD
,/,
“/NNP
suprailiac/JJ
skinfold/JJ
”/CD
was/VBD
over/IN
90/CD
,/,
or/CC
“/NN
who/WP
had/VBD
medication/NN
of/IN
hypertension/NN
”/CD
were/VBD
considered/VBN
as/IN
having/VBG
hypertension/NN
./.
====================
Table/JJ
1/CD
shows/VBZ
how/WRB
each/DT
group/NN
was/VBD
composed/VBN
of/IN
according/VBG
to/TO
our/PRP$
disease/NN
definition/NN
./.
====================
Excluding/VBG
individuals/NNS
with/IN
missing/JJ
values/NNS
among/IN
the/DT
variables/NNS
used/VBN
in/IN
this/DT
process/NN
,/,
the/DT
final/JJ
sample/NN
size/NN
was/VBD
7,389/CD
in/IN
the/DT
study/NN
./.
====================
Sex/NN
and/CC
age/NN
were/VBD
considered/VBN
as/IN
potential/JJ
covariates/VBZ
which/WDT
could/MD
affect/VB
our/PRP$
association/NN
analysis/NN
;/:
for/IN
instance/NN
,/,
coronary/JJ
heart/NN
disease/NN
(/(
CHD/NN
)/)
is/VBZ
more/RBR
common/JJ
in/IN
men/NNS
than/IN
in/IN
women/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
risk/NN
of/IN
CHD/NN
increases/VBZ
with/IN
age/NN
in/IN
both/DT
sexes/NNS
,/,
but/CC
the/DT
increase/NN
is/VBZ
sharper/JJ
in/IN
women/NNS
[/(
16/CD
]/)
./.
====================
Therefore/RB
,/,
we/PRP
divided/VBD
the/DT
7,389/CD
observations/NNS
into/IN
four/CD
groups/NNS
based/VBN
on/IN
a/DT
median/JJ
age/NN
of/IN
50/CD
years/NNS
and/CC
sex/NN
./.
====================
Group/NN
1/CD
represents/VBZ
below/IN
the/DT
median/JJ
age/NN
and/CC
males/NNS
,/,
while/IN
group/NN
2/CD
represents/VBZ
above/JJ
the/DT
median/JJ
age/NN
and/CC
males/NNS
./.
====================
Groups/NNS
3/CD
and/CC
4/CD
represent/JJ
females/NNS
below/IN
and/CC
above/JJ
the/DT
median/JJ
age/NN
,/,
respectively/RB
./.
====================
For/IN
each/DT
group/NN
,/,
our/PRP$
data/NNS
were/VBD
composed/VBN
of/IN
three/CD
different/JJ
blocks/NNS
(/(
J/NN
=/JJ
3/CD
)/)
–a/NN
gene/NN
data/NNS
block/VBP
,/,
clinical/JJ
data/NNS
block/VBP
,/,
and/CC
disease/NN
status/NN
block/VBP
./.
====================
As/IN
with/IN
many/JJ
multi-block/JJ
genomic/JJ
data/NNS
,/,
KARE/NN
data/NNS
also/RB
have/VBP
very/RB
different/JJ
characteristics/NNS
for/IN
each/DT
block/VBP
./.
====================
The/DT
gene/NN
data/NNS
block/VBP
has/VBZ
35/CD
SNP/NN
variables/NNS
that/DT
are/VBP
discrete/JJ
and/CC
can/MD
only/RB
have/VBP
values/NNS
of/IN
0/CD
,/,
1/CD
,/,
or/CC
2/CD
./.
====================
The/DT
five/CD
phenotype/NN
variables/NNS
of/IN
the/DT
clinical/JJ
data/NNS
block/VBP
were/VBD
continuous/JJ
./.
====================
The/DT
disease/NN
status/NN
block/VBP
consisted/JJ
of/IN
only/RB
two/CD
dummy/IN
variables/NNS
,/,
indicating/VBG
the/DT
presence/NN
or/CC
absence/NN
of/IN
disease/NN
./.
====================
To/TO
check/VB
the/DT
association/NN
between/IN
blocks/NNS
,/,
logistic/JJ
regression/NN
analysis/NN
was/VBD
performed/VBN
,/,
and/CC
the/DT
coefficients/NNS
and/CC
p-values/NNS
are/VBP
listed/VBN
in/IN
Table/JJ
2/CD
./.
====================
Table/JJ
2/CD
shows/VBZ
the/DT
simple/JJ
logistic/JJ
regression/NN
of/IN
the/DT
variables/NNS
in/IN
the/DT
phenotype/NN
and/CC
genotype/NN
blocks/VBZ
for/IN
diabetes/NNS
and/CC
hypertension/NN
./.
====================
In/IN
Table/JJ
2/CD
,/,
every/RB
variable/JJ
in/IN
the/DT
phenotype/NN
block/VBP
was/VBD
statistically/RB
significant/JJ
with/IN
diabetes/NNS
,/,
all/DT
with/IN
a/DT
p-value/JJ
less/RBR
than/IN
0.001/CD
./.
====================
However/RB
,/,
in/IN
the/DT
regression/NN
with/IN
hypertension/NN
,/,
the/DT
subscapular/JJ
skinfold/JJ
variable/JJ
did/VBD
not/RB
satisfy/JJ
the/DT
significance/NN
level/NN
,/,
which/WDT
turned/VBD
out/RP
to/TO
be/VB
a/DT
p-value/JJ
of/IN
0.578/CD
./.
====================
Other/JJ
than/IN
subscapular/JJ
skinfold/NN
variable/JJ
,/,
all/DT
variables/NNS
in/IN
the/DT
phenotype/NN
block/VBP
showed/VBD
significance/NN
of/IN
a/DT
relationship/NN
with/IN
hypertension/NN
./.
====================
Therefore/RB
,/,
there/EX
exists/VBZ
a/DT
relationship/NN
between/IN
each/DT
phenotype/NN
variable/JJ
and/CC
two/CD
diseases/NNS
,/,
respectively/RB
./.
====================
In/IN
contrast/NN
to/TO
the/DT
association/NN
between/IN
phenotype/NN
variables/NNS
and/CC
disease/NN
variables/NNS
,/,
the/DT
association/NN
between/IN
SNP/NN
variables/NNS
and/CC
disease/NN
variables/NNS
were/VBD
revealed/VBN
only/RB
from/IN
certain/JJ
genes/NNS
./.
====================
The/DT
genes/NNS
related/JJ
to/TO
diabetes/NNS
were/VBD
rs3856726/RB
,/,
rs3782889/NN
,/,
rs12229654/NN
,/,
rs11066280/CD
,/,
rs17092358/NN
,/,
rs1378942/NN
,/,
and/CC
rs11131794/NN
./.
====================
The/DT
genes/NNS
related/JJ
to/TO
hypertension/NN
were/VBD
rs221097/RB
,/,
rs6965746/NN
,/,
rs4472504/NN
,/,
rs9939609/NN
,/,
rs3782889/NN
,/,
rs12229654/NN
,/,
rs11066280/CD
,/,
rs7136259/NN
,/,
rs2254613/NN
,/,
and/CC
rs1378942/NN
./.
====================
There/EX
has/VBZ
been/VBN
a/DT
study/NN
of/IN
SNPs/NNS
associated/VBN
with/IN
diabetes/NNS
,/,
in/IN
which/WDT
the/DT
MYL2/NN
,/,
C12orf51/NN
,/,
and/CC
OAS1/NN
genes/NNS
were/VBD
found/VBN
to/TO
be/VB
significantly/RB
associated/VBN
with/IN
1-hPG/JJ
,/,
which/WDT
has/VBZ
been/VBN
understood/VBN
as/IN
an/DT
additional/JJ
risk/NN
factor/NN
for/IN
type/NN
2/CD
diabetes/NNS
./.
====================
Therefore/RB
,/,
genes/NNS
with/IN
rs3782889/NN
(/(
MYL2/NN
)/)
,/,
rs12229654/NN
(/(
MYL2/NN
)/)
were/VBD
proven/VBN
to/TO
have/VB
a/DT
valid/JJ
relationship/NN
with/IN
diabetes/NNS
[/(
17/CD
]/)
./.
====================
The/DT
results/NNS
of/IN
the/DT
GCCA/NN
were/VBD
analyzed/VBN
separately/RB
according/VBG
to/TO
each/DT
group/NN
./.
====================
In/IN
doing/JJ
the/DT
GCCA/NN
,/,
we/PRP
needed/VBD
to/TO
determine/VB
how/WRB
many/JJ
canonical/JJ
variables/NNS
we/PRP
would/MD
have/VBP
./.
====================
The/DT
generalized/VBN
canonical/JJ
correlation/NN
results/VBZ
are/VBP
presented/VBN
in/IN
Table/JJ
3/CD
./.
====================
Group/NN
1/CD
had/VBD
generalized/VBN
canonical/JJ
correlations/NNS
of/IN
0.183/CD
,/,
0.156/CD
,/,
and/CC
0.095/CD
./.
====================
The/DT
square/NN
of/IN
the/DT
generalized/VBN
canonical/JJ
correlations/NNS
was/VBD
0.034/CD
,/,
0.024/CD
,/,
and/CC
0.009/CD
./.
====================
The/DT
square/NN
of/IN
the/DT
generalized/VBN
canonical/JJ
correlation/NN
was/VBD
used/VBN
for/IN
calculating/JJ
what/WP
proportion/NN
the/DT
canonical/JJ
variable/JJ
explains/VBZ
the/DT
dataset/NN
./.
====================
For/IN
instance/NN
,/,
the/DT
first/JJ
canonical/JJ
variable/JJ
in/IN
group/NN
1/CD
had/VBD
a/DT
square/JJ
of/IN
the/DT
generalized/VBN
canonical/JJ
correlation/NN
value/NN
of/IN
0.034/CD
(/(
rounded/JJ
number/NN
is/VBZ
listed/VBN
in/IN
Table/JJ
4/CD
)/)
./.
====================
The/DT
proportion/NN
was/VBD
calculated/VBN
by/IN
using/VBG
the/DT
square/NN
of/IN
the/DT
generalized/VBN
canonical/JJ
correlation/NN
./.
====================
The/DT
first/JJ
GCCA/NN
canonical/JJ
variable/JJ
explained/VBN
50.2/CD
%/NN
of/IN
the/DT
variation/NN
,/,
while/IN
the/DT
second/JJ
and/CC
third/JJ
variables/NNS
explained/VBN
36.4/CD
%/NN
and/CC
13.4/CD
%/NN
,/,
respectively/RB
./.
====================
Therefore/RB
,/,
for/IN
group/NN
1/CD
,/,
we/PRP
used/VBD
two/CD
canonical/JJ
variables/NNS
that/DT
were/VBD
sufficient/JJ
enough/IN
to/TO
represent/VB
the/DT
dataset/NN
./.
====================
The/DT
other/JJ
three/CD
groups/NNS
also/RB
required/VBD
two/CD
canonical/JJ
variables/NNS
to/TO
represent/VB
the/DT
dataset.Since/NN
we/PRP
have/VBP
three/CD
blocks/VBZ
,/,
we/PRP
could/MD
make/VB
three/CD
initial/JJ
canonical/JJ
variables/NNS
./.
====================
The/DT
SNP/NN
block/VBP
’/CD
s/NNS
first/JJ
canonical/JJ
variable/JJ
was/VBD
U1/NN
=/JJ
a1SNP1/NN
+/JJ
···/NN
+/JJ
a35SNP35/NN
./.
====================
The/DT
phenotype/NN
block/VBP
’/CD
s/NNS
first/JJ
canonical/JJ
variable/JJ
was/VBD
V1/NN
=/JJ
b1SUP/NN
+/JJ
b2SUB/NN
+/JJ
b3BMI/NN
+/JJ
b4WHR/NN
+/JJ
b5WAIST/NN
./.
====================
The/DT
disease/NN
block/VBP
’/CD
s/NNS
first/JJ
canonical/JJ
variable/JJ
was/VBD
W1/NN
=/JJ
c1Diabete/JJ
+/JJ
c2Hyper/NN
./.
====================
The/DT
term/NN
ai/NN
,/,
bi/NN
,/,
ci/NNS
represents/VBZ
the/DT
coefficient/JJ
of/IN
each/DT
i-th/IN
variable/JJ
in/IN
the/DT
block/NN
./.
====================
When/WRB
we/PRP
draw/VBP
the/DT
first/JJ
canonical/JJ
variables/NNS
U1/NN
,/,
V1/NN
,/,
W1/NN
and/CC
the/DT
second/JJ
variables/NNS
U2/NN
,/,
V2/NN
,/,
W2/NN
,/,
we/PRP
can/MD
interpret/VB
the/DT
relationship/NN
of/IN
each/DT
block/VBP
’/CD
s/NNS
variable/JJ
to/TO
the/DT
other/JJ
block/VBP
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
first/RB
explain/NN
the/DT
relationship/NN
between/IN
blocks/VBZ
and/CC
then/RB
discuss/VBP
the/DT
relationship/NN
within/IN
the/DT
blocks/NNS
./.
====================
Between-block/NN
relationship/NN
====================
Once/RB
we/PRP
conducted/VBD
GCCA/NN
in/IN
SAS/IML/NN
,/,
we/PRP
could/MD
get/VB
information/NN
on/IN
the/DT
canonical/JJ
variables/NNS
and/CC
coefficients/NNS
for/IN
each/DT
variable/JJ
in/IN
the/DT
block/NN
./.
====================
From/IN
the/DT
canonical/JJ
variable/JJ
value/NN
,/,
we/PRP
calculated/VBD
the/DT
correlation/NN
between/IN
blocks/NNS
,/,
because/IN
the/DT
first/JJ
and/CC
second/JJ
canonical/JJ
variables/NNS
could/MD
represent/VB
most/JJS
of/IN
the/DT
data/NNS
./.
====================
Table/JJ
3/CD
represents/VBZ
the/DT
correlation/NN
between/IN
each/DT
block/VBP
’/CD
s/NNS
canonical/JJ
variables/NNS
./.
====================
With/IN
a/DT
GCCA/NN
containing/VBG
three/CD
blocks/VBZ
,/,
the/DT
first/JJ
correlation/NN
among/IN
three/CD
blocks/VBZ
is/VBZ
obviously/RB
high/JJ
,/,
but/CC
it/PRP
can/MD
be/VB
different/JJ
when/WRB
we/PRP
consider/VBP
two/CD
pairs/NNS
./.
====================
The/DT
highest/JJS
relationship/NN
was/VBD
found/VBN
in/IN
group/NN
1/CD
,/,
which/WDT
had/VBD
a/DT
correlation/NN
of/IN
0.281/CD
between/IN
the/DT
SNP/NN
block/VBP
’/CD
s/NNS
second/JJ
canonical/JJ
variable/JJ
and/CC
the/DT
phenotype/NN
block/VBP
’/CD
s/NNS
second/JJ
canonical/JJ
variable/JJ
./.
====================
It/PRP
is/VBZ
interesting/JJ
that/IN
the/DT
relationship/NN
between/IN
the/DT
SNP/NN
block/VBP
and/CC
phenotype/NN
block/VBP
is/VBZ
the/DT
strongest/JJS
,/,
while/IN
the/DT
relationship/NN
between/IN
the/DT
SNP/NN
block/VBP
and/CC
disease/NN
block/VBP
is/VBZ
not/RB
that/DT
noticeable/JJ
./.
====================
This/DT
would/MD
imply/VBP
a/DT
pathway/NN
relationship/NN
from/IN
SNP/NN
to/TO
disease/NN
,/,
in/IN
which/WDT
phenotype/NN
is/VBZ
the/DT
medium/NN
of/IN
the/DT
link/NN
between/IN
them/PRP
./.
====================
Another/DT
interesting/JJ
point/NN
is/VBZ
the/DT
relationship/NN
between/IN
the/DT
first/JJ
canonical/JJ
variables/NNS
is/VBZ
not/RB
that/DT
strong/JJ
in/IN
the/DT
relationship/NN
between/IN
SNP/NN
and/CC
phenotype/NN
./.
====================
Except/IN
group/NN
4/CD
,/,
the/DT
other/JJ
three/CD
groups/NNS
showed/VBD
a/DT
stronger/JJR
correlation/NN
between/IN
second/JJ
canonical/JJ
variables/NNS
than/IN
first/JJ
canonical/JJ
variables/NNS
./.
====================
This/DT
is/VBZ
thought/VBN
to/TO
be/VB
due/JJ
to/TO
the/DT
fact/NN
that/IN
the/DT
phenotype/NN
spreads/VBZ
in/IN
the/DT
second/JJ
axis/NN
./.
====================
We/PRP
also/RB
visualized/VBD
the/DT
relation/NN
between/IN
blocks/VBZ
,/,
particularly/RB
between/IN
the/DT
second/JJ
canonical/JJ
variables/NNS
of/IN
the/DT
SNP/NN
and/CC
phenotype/NN
blocks/VBZ
./.
====================
In/IN
Fig/NN
./.
====================
3/CD
,/,
we/PRP
illustrate/VBP
a/DT
sample/JJ
plot/NN
in/IN
group/NN
3/CD
./.
====================
The/DT
plot/NN
explains/VBZ
how/WRB
the/DT
sample/NN
observation/NN
is/VBZ
located/JJ
in/IN
each/DT
block/VBP
by/IN
using/VBG
the/DT
first/JJ
and/CC
second/JJ
canonical/JJ
variable/JJ
of/IN
each/DT
block/VBP
./.
====================
The/DT
SNP/NN
block/VBP
appeared/VBD
to/TO
be/VB
scattered/VBN
compared/VBN
with/IN
the/DT
other/JJ
groups/NNS
./.
====================
The/DT
phenotype/NN
block/VBP
’/CD
s/NNS
observations/NNS
are/VBP
densely/RB
populated/JJ
near/JJ
the/DT
center/NN
(/(
0,0/CD
)/)
,/,
while/IN
the/DT
disease/NN
group/NN
’/CD
s/NNS
observations/NNS
only/RB
appear/VBP
at/IN
four/CD
dots/NNS
,/,
since/IN
they/PRP
are/VBP
discrete/JJ
data/NNS
that/IN
have/VBP
four/CD
possible/JJ
disease/NN
cases/NNS
./.
====================
We/PRP
can/MD
regard/VB
a/DT
sample/JJ
that/IN
is/VBZ
located/JJ
farther/RB
from/IN
center/JJ
(/(
0,0/CD
)/)
is/VBZ
more/RBR
influential/JJ
for/IN
each/DT
SNP/NN
,/,
phenotype/NN
,/,
or/CC
disease/NN
block/VBP
./.
====================
Within-block/IN
relationship/NN
====================
If/IN
we/PRP
looked/VBD
at/IN
each/DT
block/VBP
’/CD
s/NNS
variable/JJ
plot/NN
,/,
we/PRP
can/MD
also/RB
understand/VB
how/WRB
each/DT
variable/JJ
in/IN
the/DT
block/NN
affects/VBZ
the/DT
canonical/JJ
variable/JJ
./.
====================
The/DT
variable/JJ
plot/NN
demonstrates/VBZ
how/WRB
the/DT
variables/NNS
are/VBP
positioned/VBN
within/IN
block/VBP
;/:
therefore/RB
,/,
the/DT
goal/NN
is/VBZ
figuring/VBG
out/RP
the/DT
internal/JJ
relationship/NN
between/IN
variables/NNS
./.
====================
The/DT
x-axis/NN
is/VBZ
how/WRB
much/RB
each/DT
variable/JJ
influences/VBZ
the/DT
first/JJ
canonical/JJ
variable/JJ
,/,
and/CC
the/DT
y-axis/NN
is/VBZ
how/WRB
much/RB
each/DT
variable/JJ
influences/VBZ
the/DT
second/JJ
canonical/JJ
variable/JJ
./.
====================
In/IN
Fig/NN
./.
====================
4/CD
,/,
there/EX
exist/VBP
four/CD
variable/JJ
plots/NNS
,/,
each/DT
representing/VBG
how/WRB
the/DT
variable/JJ
in/IN
each/DT
block/VBP
composes/NNS
its/PRP$
block/NN
./.
====================
The/DT
variables/NNS
of/IN
the/DT
SNP/NN
block/VBP
were/VBD
represented/VBN
as/IN
black/JJ
points/NNS
,/,
which/WDT
were/VBD
categorized/VBN
into/IN
seven/CD
different/JJ
groups/NNS
,/,
based/VBN
on/IN
where/WRB
it/PRP
is/VBZ
related/JJ
the/DT
most/JJS
./.
====================
We/PRP
can/MD
interpret/VB
variable/JJ
plots/NNS
through/IN
making/VBG
criteria/NNS
for/IN
the/DT
x-axis/NN
and/CC
y-axis/NN
./.
====================
If/IN
a/DT
variable/JJ
exists/VBZ
farther/RB
away/NN
from/IN
the/DT
origin/NN
,/,
the/DT
influence/NN
would/MD
be/VB
greater/JJR
./.
====================
We/PRP
will/MD
illustrate/VB
group/NN
1/CD
’/NN
s/NNS
case/NN
in/IN
particular/JJ
,/,
while/IN
the/DT
interpretation/NN
of/IN
the/DT
other/JJ
groups/NNS
could/MD
be/VB
made/VBN
,/,
in/IN
addition/NN
to/TO
the/DT
first/JJ
group/NN
’/CD
s/NNS
interpretation/NN
./.
====================
In/IN
group/NN
1/CD
’/NN
s/NNS
variable/JJ
plot/NN
in/IN
Fig/NN
./.
====================
4/CD
,/,
compared/VBN
with/IN
the/DT
SNP/NN
variables/NNS
,/,
phenotype/NN
and/CC
disease/NN
variables/NNS
showed/VBD
more/RBR
distinguishable/JJ
features/NNS
./.
====================
The/DT
35/CD
SNP/NN
variables/NNS
,/,
which/WDT
were/VBD
presented/VBN
as/IN
seven/CD
symbols/NNS
according/VBG
to/TO
their/PRP$
category/JJ
in/IN
the/DT
graph/NN
,/,
had/VBD
a/DT
similar/JJ
influence/NN
on/IN
SNP/NN
blocks/VBZ
./.
====================
In/IN
the/DT
phenotype/NN
block/VBP
,/,
the/DT
variable/JJ
waist-hip/NN
ratio/NN
and/CC
BMI/NN
had/VBD
almost/RB
the/DT
same/JJ
angle/JJ
from/IN
the/DT
origin/NN
,/,
whereas/IN
suprailiac/JJ
skinfold/JJ
(/(
Sup/NN
)/)
was/VBD
almost/RB
in/IN
the/DT
opposite/JJ
location/NN
in/IN
terms/NNS
of/IN
the/DT
second/JJ
components/NNS
of/IN
the/DT
phenotype/NN
blocks/VBZ
./.
====================
This/DT
means/NNS
that/DT
waist-hip/NN
ratio/NN
and/CC
BMI/NN
gave/VBD
similar/JJ
traits/VBZ
compared/VBN
with/IN
other/JJ
phenotypes/NNS
./.
====================
When/WRB
we/PRP
considered/VBD
the/DT
first-dimension/JJ
axis/NN
,/,
we/PRP
could/MD
observe/VB
that/DT
subscapular/JJ
skinfold/JJ
(/(
Sub/NN
)/)
had/VBD
a/DT
different/JJ
trait/NN
from/IN
the/DT
other/JJ
phenotype/NN
variables/NNS
./.
====================
In/IN
terms/NNS
of/IN
disease/NN
blocks/VBZ
,/,
we/PRP
could/MD
separate/VB
people/JJ
with/IN
disease/NN
and/CC
people/JJ
without/IN
disease/NN
in/IN
terms/NNS
of/IN
the/DT
x-axis/NN
,/,
and/CC
hypertension/NN
and/CC
diabetes/VBZ
were/VBD
also/RB
distinguishable/JJ
with/IN
the/DT
y-axis/NN
criteria/NNS
./.
====================
It/PRP
is/VBZ
interesting/JJ
for/IN
us/PRP
to/TO
compare/VB
how/WRB
the/DT
variable/JJ
plot/NN
in/IN
each/DT
group/NN
was/VBD
different/JJ
./.
====================
In/IN
terms/NNS
of/IN
the/DT
SNP/NN
variable/JJ
block/VBP
,/,
the/DT
rs527248/NN
SNP/NN
variable/JJ
had/VBD
a/DT
triangular/JJ
shape/VBP
,/,
which/WDT
means/NNS
the/DT
SNP/NN
is/VBZ
related/JJ
to/TO
BMI/NN
the/DT
most/JJS
compared/VBN
with/IN
the/DT
association/NN
with/IN
other/JJ
phenotype/NN
variables/NNS
./.
====================
Among/IN
SNP/NN
variables/NNS
,/,
rs527248/NN
,/,
a/DT
point/NN
located/JJ
outside/IN
of/IN
small/JJ
gray/NN
circle/NN
in/IN
the/DT
first/JJ
quadrant/JJ
,/,
had/VBD
the/DT
most/JJS
powerful/JJ
influence/NN
on/IN
its/PRP$
canonical/JJ
variable/JJ
in/IN
all/DT
groups/NNS
./.
====================
In/IN
group/NN
2/CD
,/,
the/DT
influence/NN
of/IN
the/DT
rs527248/NN
variable/JJ
was/VBD
more/RBR
powerful/JJ
on/IN
the/DT
first/JJ
axis/NN
,/,
whereas/IN
for/IN
groups/NNS
1/CD
,/,
3/CD
,/,
and/CC
4/CD
,/,
there/EX
was/VBD
much/RB
influence/VBP
of/IN
the/DT
variable/JJ
on/IN
the/DT
y-axis/NN
./.
====================
There/EX
are/VBP
different/JJ
aspects/NNS
of/IN
the/DT
phenotype/NN
block/VBP
’/CD
s/NNS
variables/NNS
from/IN
each/DT
group/NN
./.
====================
In/IN
group/NN
4/CD
,/,
there/EX
existed/VBD
extreme/JJ
difference/NN
between/IN
the/DT
phenotype/NN
variables/NNS
waist-hip/NN
ratio/NN
and/CC
waist/NN
./.
====================
Whereas/IN
the/DT
waist-hip/NN
ratio/NN
variable/JJ
was/VBD
more/RBR
than/IN
1/CD
on/IN
the/DT
y-axis/NN
,/,
the/DT
waist/NN
variable/JJ
was/VBD
near/JJ
−1/NN
,/,
which/WDT
is/VBZ
exactly/RB
the/DT
opposite/JJ
location/NN
./.
====================
If/IN
we/PRP
look/VBD
at/IN
the/DT
specific/JJ
coordinates/NNS
of/IN
the/DT
waist-hip/NN
ratio/NN
and/CC
waist/NN
variables/NNS
,/,
the/DT
influence/NN
of/IN
waist-hip/NN
ratio/NN
on/IN
the/DT
y-axis/NN
was/VBD
1.038/CD
,/,
but/CC
the/DT
influence/NN
on/IN
the/DT
x-axis/NN
was/VBD
0.4966/CD
./.
====================
In/IN
contrast/NN
,/,
the/DT
waist/NN
variable/JJ
in/IN
group/NN
3/CD
had/VBD
a/DT
stronger/JJR
influence/VBP
on/IN
the/DT
y-axis/NN
than/IN
on/IN
the/DT
x-axis/NN
./.
====================
From/IN
our/PRP$
simple/JJ
logistic/JJ
regression/NN
,/,
we/PRP
had/VBD
information/NN
that/IN
the/DT
SNP/NN
variable/JJ
rs4472504/NN
was/VBD
related/JJ
to/TO
hypertension/NN
disease/NN
,/,
which/WDT
had/VBD
a/DT
p-value/JJ
of/IN
0.031/CD
./.
====================
In/IN
our/PRP$
variable/JJ
plot/NN
,/,
the/DT
coordinates/NNS
of/IN
rs4472504/NN
were/VBD
(/(
−0.2113/CD
,/,
−0.082/CD
)/)
,/,
(/(
−0.0987/CD
,/,
0.3589/CD
)/)
,/,
(/(
−0.028/CD
,/,
0.1049/CD
)/)
,/,
and/CC
(/(
−0.0995/CD
,/,
−0.1101/CD
)/)
in/IN
each/DT
group/NN
,/,
respectively/RB
,/,
whereas/IN
the/DT
coordinates/NNS
of/IN
hypertension/NN
were/VBD
(/(
0.4645/CD
,/,
0.1513/CD
)/)
,/,
(/(
0.364/CD
,/,
0.1043/CD
)/)
,/,
(/(
0.4955/CD
,/,
0.0146/CD
)/)
,/,
and/CC
(/(
0.5504/CD
,/,
−0.0219/CD
)/)
./.
====================
Therefore/RB
,/,
we/PRP
can/MD
not/RB
conclude/VB
that/IN
the/DT
relationship/NN
between/IN
a/DT
single/JJ
SNP/NN
and/CC
a/DT
disease/NN
can/MD
not/RB
be/VB
identical/JJ
to/TO
the/DT
power/JJ
of/IN
its/PRP$
influence/NN
on/IN
each/DT
axis/NN
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
have/VBP
reviewed/VBN
how/WRB
to/TO
analyze/VB
multi-block/JJ
datasets—in/NN
particular/JJ
,/,
using/VBG
Korean/JJ
genomewide/NN
data/NNS
:/:
the/DT
KARE/NN
dataset/NN
./.
====================
We/PRP
conducted/VBD
GCCA/NN
in/IN
order/NN
to/TO
compare/VB
the/DT
relationship/NN
between/IN
and/CC
within/IN
multi-blocks/NNS
./.
====================
To/TO
see/VB
the/DT
relationship/NN
between/IN
variables/NNS
,/,
we/PRP
used/VBD
SAS/NN
[/(
18/CD
]/)
to/TO
do/VBP
GCCA/NN
and/CC
R/NN
to/TO
visualize/VB
the/DT
relationships/NNS
between/IN
and/CC
within/IN
multi-block/JJ
data/NNS
in/IN
four/CD
different/JJ
subgroups/NNS
:/:
group/NN
1/CD
,/,
group/NN
2/CD
,/,
group/NN
3/CD
,/,
and/CC
group/NN
4/CD
./.
====================
In/IN
the/DT
relationship/NN
between/IN
blocks/NNS
,/,
we/PRP
could/MD
reveal/VB
that/IN
there/EX
existed/VBD
a/DT
stronger/JJR
association/NN
between/IN
second/JJ
canonical/JJ
variables/NNS
than/IN
between/IN
first/JJ
canonical/JJ
variables/NNS
./.
====================
In/IN
addition/NN
,/,
we/PRP
found/VBD
that/IN
the/DT
relationship/NN
between/IN
SNP/NN
block/VBP
and/CC
Phenotype/JJ
block/VBP
was/VBD
the/DT
strongest/JJS
,/,
whereas/IN
the/DT
relationship/NN
between/IN
SNP/NN
block/VBP
and/CC
Disease/NN
block/VBP
was/VBD
not/RB
remarkable/JJ
./.
====================
To/TO
see/VB
the/DT
relationship/NN
within/IN
variables/NNS
,/,
we/PRP
made/VBD
plots/NNS
that/DT
showed/VBD
how/WRB
much/RB
each/DT
variable/JJ
contributed/VBD
to/TO
the/DT
canonical/JJ
variable/JJ
./.
====================
Some/DT
SNP/NN
variables/NNS
showed/VBD
distinguishable/JJ
influence/VBP
among/IN
variable/JJ
blocks/VBZ
,/,
but/CC
most/JJS
SNP/NN
variables/NNS
did/VBD
not/RB
show/VB
big/NN
difference/NN
./.
====================
Phenotype/NN
variables/NNS
,/,
however/RB
,/,
were/VBD
distinguished/VBN
by/IN
each/DT
group/NN
and/CC
showed/VBD
dramatic/JJ
differences/NNS
between/IN
groups/NNS
./.
====================
In/IN
this/DT
paper/NN
,/,
GCCA/NN
was/VBD
applied/VBN
to/TO
the/DT
preselected/JJ
SNP/NN
set/NN
which/WDT
relied/VBD
on/IN
previous/JJ
literatures/NNS
,/,
however/RB
,/,
further/RB
research/NN
could/MD
be/VB
started/VBN
from/IN
screening/VBG
SNPs/NNS
which/WDT
are/VBP
associated/VBN
with/IN
phenotype/NN
or/CC
disease/NN
status/NN
./.
====================
We/PRP
had/VBD
limitations/NNS
,/,
in/IN
that/DT
different/JJ
types/NNS
of/IN
data/NNS
,/,
including/VBG
both/CC
discrete/JJ
and/CC
continuous/JJ
data/NNS
,/,
can/MD
lead/VB
to/TO
unsuccessful/JJ
results/NNS
in/IN
GCCA/NN
./.
====================
However/RB
,/,
the/DT
analysis/NN
regarding/VBG
SNP/NN
,/,
phenotype/NN
,/,
and/CC
disease/NN
at/IN
the/DT
same/JJ
time/NN
would/MD
be/VB
meaningful/JJ
itself/PRP
and/CC
can/MD
even/RB
be/VB
more/RBR
productive/JJ
when/WRB
we/PRP
add/VBP
pathway/NN
assumption/NN
in/IN
the/DT
association/NN
analysis/NN
./.
====================
Therefore/RB
,/,
further/RB
research/NN
of/IN
this/DT
topic/JJ
should/MD
focus/VB
on/IN
robust/JJ
generalized/VBN
canonical/JJ
correlation/NN
analysis/NN
,/,
which/WDT
could/MD
function/VB
regardless/RB
of/IN
datatype/JJ
,/,
and/CC
on/IN
the/DT
relationship/NN
that/IN
we/PRP
would/MD
like/IN
to/TO
specify/VB
./.
====================
Construction/NN
of/IN
multi-block/JJ
dataset/NN
./.
====================
How/RB
to/TO
extract/NN
35/CD
single/JJ
nucleotide/NN
polymorphism/NN
(/(
SNP/NN
)/)
variables/VBZ
./.
====================
KARE/NN
,/,
Korean/JJ
Association/NN
Resource/NN
./.
====================
Sample/NN
plot/NN
of/IN
group/NN
3/CD
./.
====================
Variable/JJ
plot/NN
of/IN
each/DT
group/NN
./.
====================
SUP/NN
,/,
suprailiac/JJ
skinfold/JJ
;/:
SUB/NN
,/,
subscapular/JJ
skinfold/JJ
;/:
BMI/NN
,/,
body/NN
mass/NN
index/NN
;/:
WHR/NN
,/,
waist-hip/NN
ratio/NN
;/:
WC/NN
,/,
waist/NN
circumference/NN
;/:
HYP/NN
,/,
hypertension/NN
;/:
DIA/NN
,/,
diabetes/VBZ
./.
====================
Disease/NN
frequency/NN
according/VBG
to/TO
group/NN
====================
Simple/JJ
logistic/JJ
regression/NN
coefficients/NNS
for/IN
diseases/NNS
====================
Correlation/NN
between/IN
blocks/VBZ
====================
Generalized/VBN
canonical/JJ
correlation/NN
results/VBZ
====================
